SEC Form 4 · accession 0001209191-15-027657
Anacor Pharmaceuticals, Inc. · ANAC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lee Zane
Officer — SVP and Chief Medical Officer
Period of report
Mar 16, 2015
Accepted (ET)
Mar 18, 2015 · 7:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 16, 2015 | M | 12,000 | $6.92 | A | 40,156 | D | |
| Common StockF2 | Mar 16, 2015 | S | 7,900 | $56.2676 | D | 32,256 | D | |
| Common StockF3 | Mar 16, 2015 | S | 4,100 | $56.7587 | D | 28,156 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $6.92 | Mar 16, 2015 | M | 12,000 | D | — | Mar 31, 2021 | Common Stock | 12,000 | 40,900 | D |
Explanation of responses
- F1This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- F2The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $55.60 to $56.58, inclusive.
- F3The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $56.60 to $56.86, inclusive.
- F4This option is fully vested and exercisable.